Cancers with estrogen receptor (ER) expression of 50% or less, while technically HR+, often behave biologically like basal or triple-negative tumors. These cancers are not primarily endocrine-driven and show a significant benefit from the addition of immune checkpoint inhibitors, challenging traditional subtype classifications.

Clinicians are moving beyond strict immunohistochemistry cutoffs for treatment decisions. Tumors with low estrogen receptor expression (ER-low, <10%) are often considered not to be primarily estrogen-driven and are treated with immunotherapy-based regimens standard for triple-negative disease, reflecting a shift toward biologically-informed therapy.

A retrospective analysis of the MA27 trial suggests patients with invasive lobular cancer have worse outcomes with exemestane. This is attributed to an androgenic metabolite, prompting experts to prefer anastrozole or letrozole for this specific histological subtype.

In premenopausal patients, chemotherapy's observed benefit may be an indirect effect of inducing menopause, rather than its cell-killing properties. The ongoing OFFSET trial is testing if optimizing endocrine therapy with ovarian suppression can achieve the same risk reduction as chemotherapy, potentially avoiding chemo's side effects entirely for this group.

Even within recent major clinical trials like HER2CLIMB-05, less than half of eligible hormone receptor-positive patients received endocrine therapy. This highlights a critical and widespread gap in clinical practice, as this treatment adds significant benefit.

Selective Estrogen Receptor Degraders (SERDs) are a mechanistic advance over older therapies. While drugs like tamoxifen merely block estrogen receptors and AIs reduce estrogen, SERDs both block the receptor and trigger its complete degradation, removing the target altogether.

Citing powerful long-term data from the SOFT and TEXT trials, some oncologists are leaning away from chemotherapy for premenopausal patients with intermediate Oncotype scores (e.g., <25). They argue that the substantial, proven benefits of ovarian function suppression (OFS) may be equivalent to the chemotherapy benefit seen in trials like TAILORx.

The SET assay, measuring estrogen receptor activity, re-analyzed the NSABP B42 trial and found a 'very high SET' subgroup. This group experienced a massive 17% absolute improvement in 10-year breast cancer-free interval with extended letrozole, unmasking a profound benefit that was diluted in the overall trial results.

Uniquely, the EMPRIS window study in premenopausal patients showed geridestran monotherapy was more effective at suppressing proliferation than tamoxifen without adding an LHRH agonist. This challenges the standard practice of mandatory ovarian function suppression and could simplify treatment for younger women.